
|Videos|June 28, 2023
Evolving Standard of Care for Patients Diagnosed with Ph+ ALL
Author(s)Amanda Przespolewski, DO, Ibrahim Aldoss, MD
Drs Aldoss and Przespolewski evaluate the changing treatment landscape for patients diagnosed with Ph+ ALL.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Palbociclib Plus Trastuzumab, With/Without Pertuzumab, and ET as Maintenance in HR+, HER2+ Metastatic Breast Cancer
2
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
3
Dr O’Malley on What to Reach for Outside of a Clinical Trial in Platinum-Resistant Ovarian Cancer
4
Phase 3, Randomized Study of Talquetamab Plus Daratumumab ± Pomalidomide vs Daratumumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: MonumenTAL-3
5


















































































